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The precise identification of the HIV-1 envelope glycoprotein (Env)
responsible for productive clinical infection could be instrumental
in elucidating the molecular basis of HIV-1 transmission and in
designing effective vaccines. Here, we developed a mathematical
model of random viral evolution and, together with phylogenetic
tree construction, used it to analyze 3,449 complete env sequences
derived by single genome amplification from 102 subjects with
acute HIV-1 (clade B) infection. Viral env genes evolving from
individual transmitted or founder viruses generally exhibited a
Poisson distribution of mutations and star-like phylogeny, which
coalesced to an inferred consensus sequence at or near the esti-
mated time of virus transmission. Overall, 78 of 102 subjects had
evidence of productive clinical infection by a single virus, and 24
others had evidence of productive clinical infection by a minimum
of two to five viruses. Phenotypic analysis of transmitted or early
founder Envs revealed a consistent pattern of CCR5 dependence,
masking of coreceptor binding regions, and equivalent ormodestly
enhanced resistance to the fusion inhibitor T1249 and broadly
neutralizing antibodies compared with Envs from chronically in-
fected subjects. Low multiplicity infection and limited viral evolu-
tion preceding peak viremia suggest a finite window of potential
vulnerability of HIV-1 to vaccine-elicited immune responses, al-
though phenotypic properties of transmitted Envs pose a formi-
dable defense.
HIV-1 vaccines  transmitted HIV-1 envelope  viral evolution 
virus transmission
HIV-1 transmission in humans results most commonly fromvirus exposure at mucosal surfaces (1). For practical reasons,
by bulk or near-limiting dilution PCR amplification of viral nucleic
acid [proviral DNA or viral (v)RNA], followed by cloning, sequenc-
ing, and phylogenetic analysis (2–12). Alternatively, bulk amplified
viral nucleic acids were analyzed by heteroduplex tracking assay
(HTA) where only a small fraction of the gene of interest is
interrogated by selective annealing of a short oligonucleotide probe
followed by differential migration of the heteroduplex (5–7, 10).
Although these approaches provide an approximation of the com-
plexity of virus populations in acute and early infection, they have
significant limitations. HTA, for example, does not provide se-
quence information for phylogenetic analysis and, as a conse-
quence, allows for only qualitative inferences regarding the genetic
identity and complexity of virus populations. Bulk or near-endpoint
PCR, followed by cloning and sequencing, is compromised by the
introduction of Taq polymerase errors (15–17), Taq polymerase-
mediated template switching (recombination) (17–19), and non-
proportional representation of target sequences attributable to
template resampling or unequal template amplification and cloning
(15–17, 20). Based largely on these approaches, previous studies
generally have described the virus quasispecies in acute and early
infection either as ‘‘homogeneous,’’ reflecting transmission of one
or few viruses, or ‘‘heterogeneous,’’ reflecting a higher multiplicity
of infection (2–11). It even has been suggested that HIV-1 infection
commonly results from transmission and early replication of mul-
tiple virus variants that subsequently undergo a process of homog-
enization or purifying selection, giving rise to the appearance of a
more homogeneous infection (7).
The objective of the present study was to develop and implement
an experimental strategy that would enable us to identify unam-
biguously the transmitted or early founder env genes of viruses
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it has been impossible to identify and characterize by direct 
analytical methods HIV-1 at or near the moment of transmission, 
yet it is this virus that antibody or cell-based vaccines must interdict. 
An important step in achieving a molecular understanding of 
HIV-1 transmission and potentially in the development of an 
effective HIV/AIDS vaccine is an accurate and precise description 
of the transmitted or early founder virus (or viruses) and sequences 
evolving from them during the critical period leading to productive 
clinical infection.
Previous reports examined the molecular basis of HIV-1 trans-
mission by analyzing the genetic composition of viruses sampled 
between 1 and 6 months after infection (2–14). A common meth-
odological approach in these studies was to derive viral sequences 
from the plasma or peripheral blood mononuclear cells of patients
www.pnas.orgcgidoi10.1073pnas.0802203105
responsible for establishing productive HIV-1 infection, to track
their evolution in the critical period between transmission, peak
viremia and seroconversion, and to evaluate their phenotypic
properties. Essential to this strategy were two findings. First was the
demonstration by Leigh Brown and coworkers (15), Mullins and
coworkers (19), Coffin and coworkers (16), and Hahn and cowork-
ers (17) that single genome amplification (SGA) of HIV-1 plasma
vRNA followed by direct sequencing of uncloned amplicon DNA
precludes Taq-induced nucleotide misincorporation and recombi-
nation in finished sequences. Second were the observations by Ho
and coworkers (21, 22) and Shaw and coworkers (23, 24) that,
because of the extremely short in vivo lifespan of plasma virus and
of productively infected cells (t1/2 1 day), analysis of plasma vRNA
could provide a uniquely informative view of HIV-1 replication
dynamics and evolution. Thus, we hypothesized that an SGA-based
analysis of plasma vRNA obtained from acutely infected individuals
in the earliest stages of infection, and evaluated within the context
of a model of random viral evolution, would allow us to infer the
nucleotide sequences of env genes of viruses responsible for estab-
lishing productive clinical infection weeks earlier.
Results
Mathematical Model. We first constructed a mathematical model of
HIV-1 replication and diversification by using previously estimated
parameters of HIV-1 generation time (2 days) (22) reproductive
ratio (R0, 6) (25), and reverse transcriptase (RT) error rate (2.16
105) (26) and by assuming that the initial virus replicates expo-
nentially infecting R0 new cells at each generation and diversifying
under a model of evolution that assumes no selection [see support-
ing information (SI) Text]. Under this model, viruses would be
expected to exhibit a Poisson distribution of mutations and a
star-like phylogeny (27). This model led us to pose two hypotheses
concerning the transmitted or early founder virus: (i) the progeny
of individual virus(es) that establish productive infection can be
identified in early stages of HIV-1 infection as distinct genetic
lineages with low sequence diversity; and (ii) the consensus se-
quence of each env lineage sampled before the onset of immune
selection corresponds to the actual env sequence of transmitted or
founder virus (or viruses) responsible for establishing productive
clinical infection.
HIV-1 Envelope Sequence Diversity. We tested these hypotheses by
sequencing and analyzing 3,449 full-length env genes from plasma
vRNA from 102 HIV-1 clade B-infected subjects whom we staged
according to the Fiebig classification (28) (Fig. 1A and Dataset S1,
Dataset S2, Dataset S3, and Dataset S4). Fifty-four of the subjects
were regular donors of source plasma for whom serial specimens
were available for analysis. As part of routine blood-banking
practice, these individuals were regularly questioned (and deferred)
for homosexual encounters, sex for money, or i.v. drug use, and they
were monitored for acquisition of blood-borne infectious agents
(including HIV and hepatitis viruses) that could indicate such risk
behaviors. Forty-three other subjects admitted to high risk hetero-
sexual (n  23) or homosexual (n  20) encounters, and four had
unknown risks. Only one subject admitted to i.v. exposure as a risk.
Fifty-one subjects were viremic without detectable HIV-1 serum
antibodies at the time of study (Fiebig stages I or II), 26 others had
HIV-1 antibodies detectable by ELISA but negative (Fiebig stage
III) or indeterminate (Fiebig stage IV) by Western blot (WB), and
23 had positive WB lacking p31 bands, indicating recent infection
(Fiebig stage V). Two subjects were fully WB-positive (Fiebig stage
VI). To ensure proportional representation of plasma vRNA and
avoid in vitro-generated recombination events and Taq polymerase
errors, we used SGA of plasma vRNA followed by direct sequence
analysis of uncloned env amplicons (16, 17, 19). Sequences were
excluded if the chromatogram revealed ‘‘double peaks,’’ indicative
of amplification from more than one template or early Taq poly-
merase error. The median number of env sequences analyzed per
subject was 25 (range, 10–203). The maximum within-patient env
diversity ranged from 0.08% to 6.63%, with very low diversity found
in 81 subjects (0.08 – 0.47%) and distinctly higher diversity found
in 21 others (range 0.86–6.63%) (Fig. 1B, inset). We postulated that
the observed differences in maximum env diversity may have been
explained by differences in the numbers of viruses that infected
these individuals (5, 10), and we formally tested this hypothesis by
comparing model estimates for each subject (analyzed individually)
of the minimum number of days that would be required to explain
the observed within-patient env diversification from a single most
recent common ancestor (MRCA) sequence. In this model, we do
not adjust for mutations that are selected against and go unob-
served because they result in unfit viruses; as a consequence, the
timing estimates based on a comparison of the observed data to the
model would tend to be biased toward a low estimate. Each of 21
Fiebig stage II–VI subjects with more diverse viral sequences had
minimum estimates for days since a MRCA virus that exceeded
plausible values given their Fiebig stage (Fig. 1B). Conversely, all
but one of 81 subjects with more homogeneous sequences had env
diversities and estimated days since a MRCA that fell well within
or near model predictions (Fig. 1C), suggesting that these individ-
0.20
0.15
0.10
0.05
0.25
0.00
0.30
Maximum env diversity (%)
Fr
e
qu
en
cy
0.
0
1.
0
2.
0
3.
0
4.
0
5.
0
6.
00
5
10
15
50
55
M
ea
n 
en
v 
di
ve
rs
ity
 (%
)
0
360
480
600
M
in
im
um
 d
ay
s 
sin
ce
 M
RC
A
C
0Es
tim
at
ed
 d
ay
s 
si
nc
e 
M
R
CA
  
p24Ag +
ELISA +
120
40
80
B
Western blot +/-
10 20 30 40 50 100
A
104
103
102
101
105
106
III III IV V VI
I II III V VIIV
I II III V VIIV
vRNA +
Western blot + (p31-)
Western blot + (p31+)
  10 d
I   7 d 
II   5 d
III   3 d
IV   6 d
V   70 d
VI 
0
25
50
75
100
M
ax
im
um
 e
nv
 
di
ve
rs
ity
 (%
)
Es
tim
at
ed
 s
eq
ue
nc
e 
id
en
tit
y 
(%
)
3.0
6.0
5.0
Pl
as
m
a 
vi
ru
s 
R
N
A 
(co
pie
s/m
l)
4.0
2.0
1.0
0.0
Days following HIV-1 transmission
Fiebig StagesEclipse
Phase
open-ended
Eclipse
Plasma vRNA cut-off
240
120
Fig. 1. HIV-1 env diversity in relation to Fiebig stage. (A) Fiebig stages (28)
are defined by HIV-1 clinical laboratory test results. Blue symbols depict a
Monte Carlo simulation of env sequence identity (%) after transmission (SI
Text). Black symbols depict percentage identities in env sequences measured
sequentially in 10 subjects, each represented by a different symbol. (B) Fre-
quency distribution of within-patient maximum env diversities in all 102
subjects (Inset) and among the 21 subjects with more heterogeneous se-
quences. The vertical dashed line in the Inset represents the model prediction
of maximum achievable env diversity (0.60%; 95% C.I. 0.54–0.68%) by 100
days after transmission. Colored areas above each Fiebig stage represent
model estimates of maximum env diversity (hatched area  95% C.I.) and
corresponding minimum days since a MRCA sequence. (C) Frequency distri-
bution of within-patient mean env diversity and estimated days since MRCA
in relation to Fiebig stage for 81 subjects with more homogeneous env
sequences. Red dots in B and C and red bars in the Inset in B indicate subjects
shownbyphylogenetic analysis ofenv sequences tohavebeen infectedby two
or more viruses.
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viral lineages (Fig. 2C and Fig. S4). Four other subjects with
heterogeneous infections had samples available only from later
Fiebig stages, and in these individuals, discrete env lineages were not
discernible because of larger numbers of nucleotide substitutions
confounded by viral recombination. From the combined NJ and
Highlighter analyses and modeling, we concluded that 78 of the 102
subjects (76%) had been productively infected by a single virus (or
virus-infected cell) and 24 others (24%) had been infected by at
least two to five infectious units. Among the latter subjects, 16
(67%) had clear evidence of recombination based on visual inspec-
tion of Highlighter tracings, which was confirmed by statistical
analyses by using GARD or Recco recombination identification
tools (SI Text).
Model Testing and Analysis of HIV-1 Evolution. To explore how env
sequences sampled near peak viremia conformed to model assump-
tions, we first examined sequences from the 81 subjects with low env
diversity. For each subject, we obtained the frequency distribution
of all intersequence Hamming distances (HDs) (defined as the
number of base positions at which two genomes differ) and
determined whether it deviated from a Poisson model by using a 2
goodness of fit test. We then investigated whether or not the
observed sequences evolved under a star-phylogeny model (i.e., all
evolving sequences are equally likely and all coalesce at the
founder) in the expected time frame based on Fiebig stage.
Fifty-three (of 81) samples were consistent with both the Poisson
model and a star phylogeny (Fig. 2A, Fig. S1, and Dataset S1).
Among the samples that deviated in their mutational patterns from
a Poisson distribution, we found 13 subjects had a striking overall
enrichment for G-to-A hypermutation patterns with
APOBEC3G/F signatures (30). In six of these 13 cases, the evidence
for hypermutation was isolated to a single sequence (Fig. 3A),
whereas in seven others, G-to-A hypermutation was evident across
multiple sequences (Fig. 3B). When these APOBEC-mediated
mutations were excluded from the analysis, a good fit to the Poisson
model was restored (Fig. 3 and Dataset S2). Two other subjects
could be resolved by excluding APOBEC signature patterns from
the analysis despite the sample not being overtly hypermutated. The
remaining 13 samples had apparent branching structures based on
sublineages with a small number of shared mutations. Based on the
temporal appearance and patterns of these mutations, we could
explain these sublineages as resulting from transmission of closely
related variants of a donor quasispecies (Fig. 2B and Fig. S2A),
from stochastic mutations generated shortly after transmission (Fig.
S5), or from HLA-restricted cytotoxic T lymphocyte (CTL) escape
mutations that accumulated in patients sampled at later Fiebig
stages (Fig. S6 and Dataset S3). Sequences from subjects with
heterogeneous sequences resulting from infection by more than one
virus violated model expectations for Poisson distribution and star
phylogeny of mutations (Fig. 2C and Fig. S3) but conformed when
identifiable env sublineages were analyzed individually (Data-
set S4).
We also examined early virus diversification directly by studying
10 subjects sampled longitudinally (Dataset S5). This analysis
included a total of 1,045 complete env sequences (median of 89 per
subject; range, 57–203). Seven subjects had evidence of infection by
one virus and three subjects by more than one virus. The model
assumes that before the onset of immune selection, virus evolves
randomly with the proportion of sequences identical to the trans-
mitted virus(es) declining as depicted by the blue symbols in Fig.
1A. For subject 1058, whose plasma was sampled three times
between Fiebig stages I and IV when viral loads were increasing
from 2,737 to 26,162 to 550,000 RNA copies/ml, the proportion of
identical viral sequences declined from 89% to 59% to 45% (Fig.
4), consistent with model projections. In all ten subjects, we found
the proportion of identical env sequences to decline in a manner
that closely approximated the model until Fiebig stages V-VI, when
an abrupt decline in the proportion of identical sequences coincided
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Fig. 2. NJ, Highlighter, and HD analyses of env diversity. (A) Subject 1006. NJ 
and Highlighter show infection by a single virus with HD frequencies, con-
forming precisely to model predictions of a single virus infection (red line). (B) 
Subject 6247. (C) Subject CAAN5342. NJ and Highlighter show infection by two 
closely (B) or distantly (C) related viruses (clades 1 and 2) with HD frequencies 
that do not conform to model predictions of a single virus infection (red line). 
Subject CAAN5342 has multiple sequences representing interlineage env 
recombination after transmission.
uals had productive clinical infections originating from a single virus 
or from more than one very closely related virus.
Identification and Enumeration of Transmitted or Early Founder 
Viruses. Sequences from all 102 subjects were analyzed by using 
neighbor-joining (NJ) phylogenetic tree methods together with a 
novel sequence visualization tool, Highlighter (www.HIV.lanl.gov), 
that allows tracing of common ancestry between sequences based 
on individual nucleotide polymorphisms. In 98 subjects, we iden-
tified one or more distinct, low diversity monophyletic env lineage. 
Each lineage contained a unique set of identical or near identical 
sequences. Seventy-eight of the 81 subjects with more homoge-
neous envs (Fig. 1C) had sequences that formed single lineages in 
NJ trees (Fig. 2A and Fig. S1). Three other subjects had sequences 
that exhibited low overall diversity but were composed of two 
distinct lineages distinguished by sets of three or four nucleotide 
polymorphisms (Fig. 2B and Fig. S2A). Model projections sug-
gested that these three subjects were infected by very closely related 
viruses, most likely from a sexual partner who himself or herself was 
recently infected (29) as opposed to a single virus that evolved into 
two distinct lineages in the brief period preceding peak viremia (SI 
Text). Among the 21 subjects with greater env diversity (Fig. 1B), 17 
had sequences represented by two to five discernible lineages, 
frequently accompanied by sequences showing interlineage recom-
bination (Fig. 2C and Figs. S2–S4). We could infer that the 
recombination events resulting in most env chimeras that we 
identified occurred within the acutely infected patient after virus 
transmission (and not in the transmitting partner) because each 
recombinant contained long stretches of sequences that were 
identical or nearly identical to those of the principal transmitted
possibility that env sequences sampled near the time of peak viremia
might not coalesce to a transmitted or founder virus but instead to
a more recent common ancestor that evolved from this virus.
Several lines of evidence suggest this was not the case. First, in all
but five subjects, the estimated time to the MRCA (95% C.I.) of
sequences analyzed by Poisson and BEAST models overlapped the
estimated durations of infection based on the Fiebig stages (Dataset
S1, Dataset S2, Dataset S3, and Dataset S4); shorter estimates of
time to MRCA in three of these five subjects could be explained by
overcompensation for G-to-A hypermutation. Second, the fre-
quency of HIV-1 RT-mediated nucleotide misincorporation affect-
ing a gene the length of env (2,600 bp) in a single infection cycle
is small (2 105 2,600 0.05, or one env mutation in every 20
virus infection events), and most mutations would be expected to
be neutral or deleterious. We found evidence for the latter in a
statistically significant trend for lower than expected dN/dS ratios
in env genes of viruses from Fiebig stage I and II subjects (P 0.01
by Wilcoxon signed rank test with continuity correction). Third, the
relatively long HIV-1 generation time (2 days), low R0 (10), and
brief eclipse period (10 days) provide little time or opportunity for
generation and outgrowth of a selected variant, a conclusion
supported by model projections (SI Text). We recognize that virus
recombination at the initial infection event is possible, but this
would have negligible impact if vRNA is homozygous; if the
transmitted virus was heterozygous (heterodimeric) and recombi-
nation did occur, then the progeny from that cell would represent
the founder virus just one step removed from the transmitted virus.
Finally, we used SGA to obtain 908 full-length env sequences from
43 chronically infected, treatment-naı¨ve subjects (Dataset S6).
Maximum within-subject env diversity among the chronic subjects
ranged from 0.77 to 5.4%, essentially overlapping the range of HDs
found in the samples from the 21 acute patients infected by more
than one divergent virus (Fig. 1B). In none of the chronically
infected subjects did we find predominant low diversity lineages
comparable to those found in acutely infected subjects. Thus, we
conclude that in the 98 subjects in whom we identified discrete low
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Fig. 4. NJ andHighlighter analysis of sequential env sequences from subject
1058. Sequences depicted by yellow, orange, and brown bars correspond to
sample dates March 8, 1998 (Fiebig stage I), March 11, 1998 (Fiebig stage II),
andMarch 18, 1998 (Fiebig stage IV) (Dataset S5). At these time points, plasma
vRNA levelswere 2,737 copies perml, 26,162 copies perml, and 550,000 copies
per ml, respectively. The proportion of identical sequences corresponding to
the transmitted or early founder env decreased from 89% to 59% to 45%,
consistent with model projections illustrated by the blue symbols in Fig. 1A.
Fig. 3. Effect of APOBEC3G/F-mediated G-to-A hypermutation on HD fre-
quency distribution. HD (x axis) is plotted versus frequency (y axis) as in Fig. 2. 
G-to-A hypermutations primarily in one sequence (A) or distributed in multi-
ple sequences (B). Hypermutated sequences do not conform to model predic-
tions for HD frequency distribution (red lines) but do conform if APOBEC3G/F 
related G-to-A mutations are eliminated.
with selection for CTL escape mutants. This is illustrated for subject 
WEAU0575 (Fig. S6), where 29 of 30 env sequences mutated in a 
single confirmed HLA-restricted CTL epitope over a period of 29 
days as the patient progressed from Fiebig stage II to V. Impor-
tantly, in none of these 10 individuals did we find evidence of a 
transmitted virus lineage that was lost during the acute infection 
period before peak viremia, nor did we find evidence, aside from 
CTL escape variants, of a predominant viral lineage that appeared 
de novo.
Although the empirical results suggested that HIV-1 env se-
quences sampled near peak viremia coalesce to virus(es) at or near 
transmission, we considered alternate explanations. We first con-
sidered limitations imposed by virus sampling. With a sample of at 
least 20 plasma vRNA sequences (which was the case for 81 of 102 
subjects), we could be 95% confident that a given missed variant 
comprised less than 15% of the virus population (SI Text). Sampling 
biases were further minimized by sequential analyses in 10 subjects 
and by additional SGAs by using different primer sets that amplified 
env, a 7kb gag–env fragment, or the complete 9-kb viral genome 
(G.M.S., unpublished data), all of which gave identical results. Thus, 
sampling biases are unlikely to affect substantially our conclusions 
regarding the minimum number or identity of the viral lineages that 
established productive clinical infection. We also considered the
ments showing that sCD4 at subinhibitory concentrations (equal to
the IC50 of sCD4 for each virus) could trigger a conformational
change in gp120 and render the virus susceptible to neutralization
by 447-52D and/or F425-B4e8. As a group, transmitted Envs were
different from chronic Envs in that three chronic Envs were
X4-dependent and two were CCR5/X4 dual-tropic, whereas only 1
of 55 transmitted Envs was R5/X4 tropic (Fisher exact test, P 
0.017). In addition, Envs from three chronically infected subjects
were unusually sensitive to sCD4 and to the mAb 17b and to certain
other gp120 or gp41 ligands; such globally heightened neutraliza-
tion sensitivity was not seen in any of the transmitted Envs. Finally,
we observed evidence of a modest (2- to 4-fold) heightened
resistance of acute Envs compared with chronic Envs to T1249,
4E10, and 2F5 but not to HIVIG or other Env ligands (Fig. 5 and
Dataset S7). We note that some of the Envs that we studied were
derived from the same patients and thus were not independent.
Trends for greater neutralization resistance in transmitted Envs
were still observed after using a resampling scheme incorporating
a single sequence from each patient for the ligands T1249, 4E10,
and 2F5 (SI Text). These findings are different from those reported
by Rusert et al. (13), possibly owing to the timing of sample
acquisition or the effects of in vitro virus cultivation on HIV-1 Env
receptor binding in the latter study. We caution that our study was
not designed prospectively or powered statistically to make a robust
comparison of the sensitivity of transmitted/founder Envs versus
chronic Envs to broadly neutralizing envelope ligands, and thus
these findings should be considered exploratory.
Discussion
The present study builds on a large body of published work on acute
HIV-1 infection (2–14) by shedding new light on the genetic and
phenotypic properties of HIV-1 at or near the moment of trans-
mission and in the critical period of virus replication and diversi-
fication leading to peak viremia and antibody seroconversion.
Among 102 subjects, we found that 78 (76%) had evidence of
infection by a single virus or virus-infected cell and that 24 others
(24%) had evidence of infection by at least two to five viruses. Aside
from early selection of CTL escape variants found in several
subjects, there was no suggestion of virus adaptation to a more
replicative variant or bottlenecking in virus diversity (7) preceding
peak viremia. Our findings regarding the number of viruses leading
to productive clinical infection are minimal estimates, and addi-
tional viruses could conceivably have been transmitted but not
sufficiently propagated in vivo to allow detection within the scope
or timing of our sampling. We note, however, that our observation
of a low number of transmitted viruses (range, 1–5; median 1) is
consistent with epidemiological observations of the relative ineffi-
ciency of virus transmission by most sexual routes (1, 29). These
considerations notwithstanding, we interpret the findings of low
multiplicity infection and limited viral evolution preceding peak
viremia to suggest a crucial but finite window of potential vulner-
ability of HIV-1 to vaccine-elicited immune responses.
Previous studies characterized HIV-1 env sequences in acute and
early infection by using methods that did not involve SGA and direct
sequencing, and, as a result, they did not allow for the precise
identification or enumeration of transmitted or early founder envs,
their pathways of diversification as genetic units, or their corre-
sponding phenotypes (2–14). The extent to which differences in
experimental approach can impact the interpretation of virus
complexity was recently highlighted in a study of acute and early
HIV-1 clade C infection (17) and was seen again in the present
study in 10 subjects who had been analyzed previously by the HTA
method (10). In this latter example, SGA and HTA methods were
concordant in identifying five acute subjects (Z02, Z05, Z13, Z20,
and Z27) infected by a single virus but were discordant in defining
the number and identity of transmitted viruses in five others (Z30,
Z18, Z03, Z10, and Z29). Reanalysis of all 26 subjects in that study
(10) led to the conclusion that 80% of subjects (not 50%, as
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Fig. 5. Neutralization sensitivity of transmitted Envs compared with chronic 
Envs. Red dots represent the IC50 of the transmitted viral Envs, and yellow bars 
represent the interquartile range, with the median value indicated as the gap 
between the bars. Black dots and gray bars represent chronic Envs. The dots 
clustered above the thin black lines are Envs that were not neutralized at the 
highest concentration of ligand tested. Results for anti-Env mAbs (A), sCD4 
and HIVIG (B), and the fusion inhibitor T1249 (C) are depicted. Uncorrected P 
values at the base of the figure were calculated by using a Wilcoxon rank-sum 
statistic comparing transmitted and chronic Envs. A total of 20 comparisons 
were made (Dataset S7); hence, to be significant after consideration of mul-
tiple tests, a significance level of 0.0025 was required. P values of 0.0025 are 
in red.
diversity viral env lineages, these lineages most often coalesce to env 
sequences of actual transmitted viruses. In instances where they do 
not, then they coalesce to early founder viruses only one or few 
replication steps removed from the transmitted virus.
Phenotypic Analysis of Transmitted or Early Founder Envs. The 
identification of viral env genes responsible for productive clinical 
infection enabled us to examine the phenotypic properties of Env 
glycoproteins most relevant to natural virus infection. We tested 55 
Envs from 45 acutely infected subjects compared with 29 SGA-
derived Envs from 13 chronically infected clade B patients for their 
coreceptor usage and sensitivity to human mAbs specific for the 
HIV-1 Env CD4 receptor and coreceptor binding sites (b12 and 
17b, respectively); surface glycans (2G12); V3 loop (447-52D, 
F425-B4e8); membrane proximal external region of gp41 (2F5, 
4E10, Z13e1); a polyclonal human HIV immune globulin 
(HIVIG); soluble CD4 (sCD4); the fusion inhibitor T1249; core-
ceptor inhibitors TAK779 (CCR5) and AMD3100 (CXCR4); and 
the anti-CD4 mAb RPA-T4. Each of the 55 Envs corresponding to 
transmitted or early founder viruses was biologically functional in 
mediating CD4 dependent virus entry. Fifty-four Envs were CCR5 
tropic, and one was CCR5/X4 dual-tropic (Dataset S7), indicating 
that the R5 phenotype is a property of the transmitted virus per se 
and not one that evolves during acute or early infection (14, 31). All 
transmitted or founder Envs were sensitive to one or more of the 
broadly neutralizing antibodies IgG1b12, 2G12, 4E10 or 2F5 and 
most were neutralized by HIVIG at concentrations less than 1,000 
g/ml (equivalent to a 1:10 plasma dilution) (Fig. 5, Fig. S7, and 
Dataset S7). Transmitted or founder Envs were uniformly resistant 
to 17b, and all but three were resistant to the V3 loop mAbs 
447-52D and F425-B4e8. Evidence that V3 epitopes in some Envs 
were conformationally masked and not absent came from experi-
suggested by HTA) had been productively infected by a single virus
(G. Schnell and R.S., unpublished observations), a finding more in
keeping with the present report.
Differences in risk behaviors, routes of virus transmission, clin-
ical stage and viral load in the infected partner, and comorbid
clinical conditions influence the frequency of HIV-1 transmission
(1, 29) and likely could affect the numbers of viruses transmitted
and subsequent disease natural history. All are factors relevant to
vaccine design and evaluation. In the present study, a substantial
proportion of the subjects had limited behavioral information
available for analysis; therefore, we could draw no firm conclusions
regarding particular risk factors and the likelihood of single versus
multiple virus transmission. However, we did note that among men
who acknowledged sex with men (MSM), half had been acutely
infected by more than one virus strain from their HIV-infected
partner. This was also true for the one injecting drug user who
acknowledged sharing needles with an HIV-positive partner. We
are currently examining this question of risk factors for multiple
virus acquisition in additional well-defined acute infection cohorts
by using SGA-based strategies.
Our finding in 98 of 102 subjects that the SGA-direct sequencing
approach could unambiguously identify transmitted or early
founder envs provided an unparalleled opportunity to characterize
those envelope genes and proteins most relevant to virus transmis-
sion and vaccine development. When such envs were cloned,
expressed, and analyzed phenotypically, we found all to be biolog-
ically functional in conferring CD4-dependent and CCR5-
dependent cell entry. We explored the possibility that viruses
responsible for productive clinical infection in naı¨ve individuals who
are devoid of preexisting neutralizing antibodies may rapidly adapt
(or be preselected) for preferential replication in this environment,
but we found no genetic or phenotypic evidence for this. To the
contrary, most viral env sequences coalesced to a MRCA near the
time estimated for transmission based on Fiebig staging; coreceptor
binding surfaces on transmitted/founder Envs (probed by 17b,
447-52D, and F425-B4e8) were conformationally masked; and
transmitted/founder Envs were comparable to primary virus strains
(32) in their susceptibility to broadly neutralizing antibodies. Stud-
ies aimed at further analyzing Env glycoproteins of transmitted or
early founder viruses may help to identify unique features and
potential vulnerabilities relevant to vaccine design. Beyond this, the
present study illustrates a strategy for identifying and characterizing
full-length genomes and proteomes of transmitted or early founder
viruses including, but not limited to, HIV-1. Such analyses may
facilitate a better understanding of virus natural history and virus-
specific cellular and humoral immune responses in naı¨ve and
vaccinated individuals.
Methods
Plasma HIV-1 RNA sequences were derived by SGA-direct amplicon sequencing
(17) and can be accessed at GenBank (EU574937–EU579293) with edited env
alignments at www.hiv.lanl.gov/content/sequence/hiv/useralignments/keele. A
model of random virus diversification and power calculations for estimating the
likelihood of detecting infrequent transmitted env variants are presented in SI
Text (see also Figs. S8 and S9). Env genes were molecularly cloned and analyzed
by Env pseudotype cell entry assay (24).
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